Precision has agreed to develop for Novartis a single custom ARCUS sequence-specific DNA-cutting enzyme, or nuclease, designed to insert in vivo, a therapeutic transgene at an undisclosed “safe harbor” location in the genome where a new gene can be added without otherwise affecting the patient’s DNA of gene expression patterns. Precision has agreed to issue an exclusive license for the custom ARCUS nuclease to Novartis for further development . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge